

October 31, 2026

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Subject: Press Release

Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated October 31, 2026.

This is for your information and for public at large.

Thanking you,

Yours faithfully,

For Advanced Enzyme Technologies Limited

SANJAY
PRAKASH
BASANTANI
Date: 2026.10.31
14:40:34 +05'30'

Sanjay Basantani

Company Secretary and Head – Legal

Encl.: As above

FOR IMMEDIATE RELEASE

QUARTERLY EARNINGS RELEASE

Thane, India: Saturday, October 31, 2026

Advanced Enzyme Technologies Limited announces Financial Results for Second Quarter and Half Year ended September 2026

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes & probiotics, today announced their unaudited financial results for second quarter and half year ended September 2026.

CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

(Amount in INR Mn.)	Q2 FY27	Q1 FY27	Q2 FY26	Change (Y-o-Y %)	Change (Q-o-Q %)	H1 FY27	H1 FY26	Change (%)
Revenue	2,145	1,917	1,845	16%	12%	4,062	3,704	10%
EBITDA	721	529	601	20%	36%	1,250	1,165	7%
EBITDA Margin (%)	34%	28%	33%			31%	31%	
PAT	512	386	447	14%	33%	897	852	5%
PAT Margin (%)	24%	20%	24%			22%	23%	
EPS	4.33	3.31	3.87	12%	30%	7.64	7.44	3%

CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 2,145 million in Q2 FY27 from ₹ 1,845 million in the Q2 FY26, a growth of 16%.

Profit:

Consolidated EBITDA during Q2 FY27 stands at ₹ 721 million as compared to ₹ 601 million during Q2 FY26, increased by 20%.

Profit before tax stands at ₹ 688 million during Q2 FY27 as against ₹ 595 million in Q2 FY26, increased by 15%.

Profit after tax grew by 14% and stands at ₹ 512 million during Q2 FY27 as compared to ₹ 447 million during Q2 FY26.

Margin:

EBITDA margin stands at 34%, PBT margin stands at 32% and PAT margin stands at 24% during the quarter.

Financial Costs:

Financial costs stood at ₹ 12 million during Q2 FY27 as against ₹ 7 million in Q2 FY26.

Depreciation and Amortization:

Depreciation and Amortization charge for Q2 FY27 stood at ₹ 109 million as compared to ₹ 101 million in the same quarter previous year.


Earnings Per Share:

Earnings Per Share during Q2 FY27 stands at ₹ 4.33 as compared to ₹ 3.87 in Q2 FY26.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q2 FY27	Q2 FY26	Change (%)
Human Nutrition	1,285	1,212	6%
Animal Nutrition	265	193	37%
Bio-Processing	365	255	43%
Specialized Manufacturing	231	185	25%



The total revenue from operations grew by 16% on y-o-y basis and 12% on q-o-q basis.


Revenue from the Human Nutrition segment increased by 6% y-o-y to ₹1,285 million in Q2 FY27, compared with ₹1,212 million in Q2 FY26. This growth was primarily attributable to improved sales in the Pharma/API business, Biocatalysis and Nutrition business.

The Animal Nutrition segment reported a growth of 37% on y-o-y basis to ₹265 million in Q2 FY27, compared with ₹193 million in Q2 FY26.

The Bio-Processing segment delivered a strong performance during the quarter, with revenue growing 43% y-o-y to ₹365 million in Q2 FY27, compared with ₹255 million in Q2 FY26. Within the segment, the Food business recorded robust growth of 48% y-o-y, achieving revenue of ₹305 million in Q2 FY27. Meanwhile, the Non-Food business registered growth of 21% y-o-y, with revenue reaching ₹60 million during the quarter.

The Specialized Manufacturing segment contributed 11% to the Company's total revenue during the quarter, with revenue increasing by 25% y-o-y to ₹231 million.

Geographical Revenue:



Domestic sales accounted for ₹ 1,110 million in Q2 FY27 as compared to ₹ 887 million in Q2 FY26, higher by 25%.

The total revenue comprises of International sales amounting to ₹ 1,035 million in Q2 FY27 as compared to ₹ 958 million in Q2 FY26, an increase of 8%. The revenue grew by 4% in Americas, 6% in Asia (ex-India) and 156% in the rest of the world while registered a de-growth of 10% in Europe.

The domestic sales constituted about 52% of revenue from operations during Q2 FY27 as compared to 48% during Q2 FY26. International sales were 48% of revenue from operations during Q2 FY27 as compared to 52% during Q2 FY26.

CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 2,145 million in Q2 FY27 from ₹ 1,917 million in Q1 FY27, a growth of 12%.

Profit:

Consolidated EBITDA during Q2 FY27 stands at ₹ 721 million as compared to ₹ 529 million during Q1 FY27, higher by 36%.

Profit before tax stands at ₹ 688 million during Q2 FY27 as against ₹ 535 million in Q1 FY27, increased by 28%

Profit after tax grew by 33% and stands at ₹ 512 million during Q2 FY27 as compared to

₹ 386 million during Q1 FY27.

Financial Costs:

Financial costs increased to ₹ 12 million during Q2 FY27 as compared to ₹ 6 million in Q1 FY27.

Depreciation and Amortization:

Depreciation and Amortization charge for Q2 FY27 is ₹ 109 million as compared to ₹ 99 million in the last quarter.

Earnings Per Share:

Earnings Per Share during Q2 FY27 stands at ₹ 4.33 as compared to ₹ 3.31 in Q1 FY27.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q2 FY27	Q1 FY27	Change (%)
Human Nutrition	1,285	1,158	11%
Animal Nutrition	265	252	5%
Bio-Processing	365	306	19%
Specialized Manufacturing	231	200	15%

The human nutrition segment reflected a growth 11% to ₹ 1,285 million in Q2 FY27 as compared to ₹ 1,158 million in Q1 FY27.

Geographical Revenue:

Domestic sales accounted for ₹ 1,110 million in Q2 FY27 as compared to ₹ 937 million in Q1 FY27, a growth of 18%. The domestic sales constituted about 52% of revenue from operations during Q2 FY27 as compared to 49% during Q1 FY27.

Total revenue comprises international sales of ₹1,035 million in Q2 FY27, compared to ₹980 million in Q1 FY27, representing a growth of 6%.

The Animal nutrition grew by 5% to ₹ 265 million in Q2 FY27 as against ₹ 252 million in Q1 FY27.

The Bio-Processing segment recorded a 19% q-o-q growth in revenue to ₹365 million in Q2 FY27, compared with ₹306 million in Q1 FY27. Within the segment, the Food business recorded a 16% q-o-q increase in revenue to ₹305 million, while the Non-Food business registered a 37% q-o-q growth to ₹60 million.

The Specialized manufacturing segment registered a growth of 15% to ₹ 231 million in Q2 FY27 from ₹ 200 million in Q1 FY27.

Revenue grew by 2% in the Americas, 12% in Asia (ex-India), and 103% in the Rest of the World, while Europe registered a decline of 21%.

International sales were 48% of revenue from operations during Q2 FY27 as compared to 51% during Q1 FY27.

CONSOLIDATED HALF YEARLY FINANCIAL REVIEW (YTD basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 4,062 million in the H1 FY27 from ₹ 3,704 million in the H1 FY26, reported higher by 10%.

Profit:

Consolidated EBITDA during H1 FY27 stands at ₹ 1,250 million as compared to ₹ 1,165 million during H1 FY26, growth of 7%.

Profit before tax stands at ₹ 1,223 million during H1 FY27 as against ₹ 1,144 million in H1 FY26, an increase of 7%.

Profit after tax stands at ₹ 897 million during H1 FY27 as compared to ₹ 852 million during H1 FY26, an increase of 5%.

Margin:

EBITDA margin stands at 31%, PBT margin stands at 30% and PAT margin stands at 22% during the H1 FY27.

Financial Costs:

Financial costs stood at ₹ 18 million during H1 FY27 as against ₹ 15 million in H1 FY26.

Depreciation and Amortization:

Depreciation and Amortization charge for the H1 FY27 is ₹ 208 million as compared to ₹ 197 million in H1 FY26.


Earnings Per Share:

Earnings Per Share during H1 FY27 stands at ₹ 7.64 as compared to ₹ 7.44 in H1 FY26.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	H1 FY27	H1 FY26	Change (%)
Human Nutrition	2,443	2,434	0.4%
Animal Nutrition	517	452	14%
Bio-Processing	671	491	37%
Specialized Manufacturing	431	327	32%



The Human Nutrition segment remained flat reaching ₹2,443 million in H1 FY27, compared to ₹2,434 million in H1 FY26.


The Animal Nutrition segment also demonstrated growth, increasing by 14% to ₹517 million in H1 FY27, up from ₹452 million in H1 FY26.

The Bio-Processing segment grew by 37% during the first half, contributing ₹671 million in H1 FY27, compared to ₹491 million in H1 FY26. Within this segment, the Food business accounted for 14% of

total revenue, reaching ₹568 million, delivering 49% growth, while the Non-Food business contributed 3%, amounting to ₹103 million, with 7% decline.

The Specialized Manufacturing segment accounted for 11% of total revenue, registering an impressive growth of 32% YTD and generating revenue of ₹431 million in H1 FY27.

Geographical Revenue:



International sales grew by 10% y-o-y to ₹2,015 million in H1 FY27, compared to ₹1,839 million in

H1 FY26. Revenue grew by 2% in the Americas, 14% in Europe, 19% in Asia (excluding India), and 54% in the Rest of the World.

Domestic sales grew by 10% y-o-y to ₹2,047 million in H1 FY27, compared to ₹1,866 million in H1 FY26.

Domestic sales contributed approximately 50% of total revenue from operations, remaining broadly in line with H1 FY26. International sales accounted for the remaining 50%, also maintaining a similar contribution compared to H1 FY26.

OUTLOOK 2026-27

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

Human Nutrition:

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

Animal Nutrition:

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

Probiotics:

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal

Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

Bio Catalysis:

The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

Baking:

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

Research & Development:

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

Inorganic expansion:

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.

RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 3rd November 2026, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, www.advancedenzymes.com

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: +91 22 6280 1403 / +91 22 7115 8304

[Pre-registration link](#)

For further information, please contact:

Ronak Saraf

Investor Relations

✉ ir@advancedenzymes.com

CORPORATE INFORMATION:

Advanced Enzyme Technologies Limited
Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica,
Louiswadi, Thane (W) -400 604,
Maharashtra, India
Tel.: +91 22 41703200
Fax: +91-22 25835159
Website: www.advancedenzymes.com
CIN No: L24200MH1989PLC051018